This article first appeared on GuruFocus .
Release Date: October 30, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Shaily Engineering Plastics Ltd ( BOM:501423 ) reported its highest-ever quarterly revenue of INR 320 crores, up 24% YoY and 14% QoQ, with EBITDA crossing INR 100 crores for the first time.
-
Healthcare segment revenue surged 78% YoY to INR 175 crores, contributing 55% of total revenue, driven by strong demand for GLP-1 pen injectors and other devices.
-
Gross margins recovered to 60%, up 70 basis points YoY, and EBITDA margin stood at 31.9%, reflecting pricing discipline and favorable product mix.
-
The company launched its innovative Tobii Reusable Autoinjector, which is 70% more sustainable than disposable alternatives, and signed two new contracts for its proprietary platforms.
-
Credit rating upgraded to CARE A1+ for short-term facilities, with ROCE and ROE at 41.1% and 29.7% respectively, indicating strong financial health and returns.
Negative Points
-
Consumer segment revenue declined 14% YoY to INR 116 crores, with demand for home furnishings in Europe and the US remaining subdued, impacting overall growth.
-
Exports accounted for 62.9% of H1FY27 revenue, down from 71.7% in H1FY26, due to a shift toward supplying Indian pharma customers, which may affect direct export earnings.
-
Other expenses rose 45% QoQ, including some one-off costs, and the company could not quantify the one-off portion, raising concerns about cost transparency.
-
The UK subsidiary incurred recurring losses for the last two quarters, and revenue recognition was delayed due to pending customer confirmations, though full-year profitability is expected.
-
Pricing pressure persists in long-term contracts, with 10-15% erosion built in, and while margins are expected to be maintained through operating leverage, the impact on profitability remains a risk.
Q & A Highlights
Q: With healthcare now the primary growth engine, can you update on the FY27 device volume guidance and the outlook for FY28? A: Amit Sanghvi (Managing Director) said the company remains confident of exceeding its full-year guidance of 36 million devices, though he declined to quantify the upside, noting that pressure on capacity is easing but not yet fully resolved. For FY28, he indicated a target of roughly 50 million devices, give or take 15%, while cautioning that this is not formal guidance since the product has launched in only three markets and there is insufficient data to forecast precisely.
Q: What is the rationale behind the new Tobii Reusable autoinjector, and will it cannibalize the existing disposable product portfolio? A: Amit Sanghvi (Managing Director) explained that Tobii Reusable retains the simple two-step interaction of the disposable version while introducing a multi-use format, where a single-use syringe pod attaches to a mechanism reused for over 200 injections. He said it is conservatively 70% more sustainable than a disposable two-step autoinjector, reducing material consumption, shipping and cold chain requirements. He does not expect cannibalization, as the product targets innovator pharma rather than generics, and believes it can sustain equal or higher profitability while offering customers a differentiated, sustainability-linked solution.
Q: Can you clarify the recent regulatory recall related to incorrect dose display and packaging errors, and whether it impacts Shaily? A: Amit Sanghvi (Managing Director) clarified that the recall relates to a variant of the pen that carried an incorrect label, where the label indicated one dose while the pen was actually for a different dose. He stated there is no attribution to Shaily for the recall, as the issue pertains to final assembly, packaging or distributors. He added that demand remains strong, even stronger, and the company is focused on qualifying its newly installed line.
Q: Given the pricing pressure in GLP-1 pens, how confident are you of maintaining margins over the next two years? A: Amit Sanghvi (Managing Director) acknowledged pricing pressure but noted that erosion has already been built into existing long-term contracts. He expressed confidence in maintaining margins, citing that operating leverage has not yet kicked in at roughly 52% capacity utilization, and that an index mechanism passes on material price inflation. Sanjay Shah (Chief Strategy Officer) added that the change in average revenue per device reflects a shift from insulin contract manufacturing to higher-realization GLP-1 supply.
Q: What is the status of the on-body injector program and the emergency-use autoinjector, including monetization timelines? A: Amit Sanghvi (Managing Director) said the company is close to finalizing a customer for the on-body MIRA device, after which a 14-month timeline applies to deliver clinical batches. For the emergency-use autoinjector, two active customers are developing the product, with clinical batches due by end-2027 and earliest commercialization likely by end-2028. He added that the high-volume applicator has completed qualification and supply should begin by the end of this quarter or early next quarter.
Q: When will the newly added 25 million pen capacity begin commercial sales, and how should we think about quarterly revenue from here? A: Amit Sanghvi (Managing Director) said the new line starts qualification next week and, if all goes well, commercial sales from that capacity should begin in December. Sanjay Shah (Chief Strategy Officer) said the consumer business will likely steady at current levels for the rest of the year, with growth expected next year depending on geopolitics and the global situation.
Q: What is the opportunity in consumer electronics and semiconductor packaging, and what capex is envisaged? A: Amit Sanghvi (Managing Director) said commercial supplies for consumer electronics have commenced and production of the five awarded components is scaling, while semiconductor packaging trial production starts in Q3 FY27 with commercial shipments from Q4 FY27. He sees a significant scale-up opportunity over the next 36 months. On capex, he indicated around INR 100 crores as a reasonable starting estimate, with a possible range of INR 80-120 crores.
Q: What is the strategy for the semiconductor packaging business, and how do you compete with Malaysian and Chinese players? A: Sanjay Shah (Chief Strategy Officer) said the company will target carrier tapes and related packaging products, leveraging a tie-up with a Korean partner that has worked with over 150 customers globally, which should speed up product acceptance by replicating established manufacturing processes. He said the company will start with small capacity and add more as demand becomes clear, and expects margins better than the average for the consumer and industrial business.
Q: What is the outlook for cracking innovator customers, and why does revenue take three to four years to materialize? A: Amit Sanghvi (Managing Director) said conversations are progressing and the company is participating in RFQs, and he is fairly confident of onboarding one or two innovators by the end of calendar 2027. He explained that participation typically happens on new molecules at the phase two or phase three stage of the customer, and the journey to the customer's own approval takes about three years, which is why revenue flows only after three to four years.
Q: What is the status of the UK subsidiary's losses, and will it be profitable for the full year? A: Sanjay Shah (Chief Strategy Officer) said the subsidiary has made a loss for the last two quarters, partly because some revenue was not recognized in Q2 pending customer confirmations. He stated that on an overall basis for the whole year, the subsidiary would not have a loss. Amit Sanghvi (Managing Director) confirmed the expectation of being EBITDA positive and PAT positive for the full year.
Q: How is the consumer business faring, and how are polymer price increases being passed through? A: Sanjay Shah (Chief Strategy Officer) said consumer demand in Europe and the U.S. remains weak, with recovery dependent on the global situation and inflation. On pricing, he said inflation is passed on with a lag that varies by customer, ranging from about two months to three to four months. He added that the company has been consistently adding new products in the home segment over the last several quarters to build a broader portfolio for ramp-up when volumes recover.
Q: What is the split between GLP-1 and
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
